Urease Market Size, Share, Growth, and Industry Analysis, By Type (Plants Urease,Fungi & Others Urease), By Application (Biotechnology,Medicine,Chemical), Regional Insights and Forecast to 2035

Urease Market Overview

The global Urease Market is forecast to expand from USD 61.35 million in 2026 to USD 64.27 million in 2027, and is expected to reach USD 93.23 million by 2035, growing at a CAGR of 4.76% over the forecast period.

Plant-derived urease comprises approximately 90.96 % of the global urease production-value market, while fungi and others make up around 9.04 % as of 2024. Urease catalyzes hydrolysis of urea to ammonia and CO₂ and finds use in biosensors, clinical chemistry, environmental management, agriculture, biotechnology, and industrial applications. Plant urease execution has been above 91 % share from 2018 to 2023. The global urease industry processes urea in diagnostics and agro-applications with market-value presence around USD 55.66 million in 2024.

In the United States, urease is widely adopted in clinical diagnostics, with more than 23 million urea breath tests conducted annually for Helicobacter pylori detection. Urease usage in agricultural soil leads to rapid hydrolysis, with over 68 % of applied urea undergoing enzymatic breakdown, according to ICAR studies. The U.S. urease market accounts for approximately 14.8 % of the global market share when China (25 %) and Europe (30 %) are considered in comparison.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Agricultural enzyme usage rose by 37 %, driven by improved nitrogen efficiency in fertilizers.
• Major Market Restraint: Enzyme instability and limited shelf life affect 28 % of industrial applications, hampering adoption.
• Emerging Trends: Biotechnology integration and enzyme immobilization techniques have improved urease performance by 33 %.
• Regional Leadership: Asia-Pacific leads with a 41 % share of the global market due to strong agriculture and biotech demand.
• Competitive Landscape: Top manufacturers control about 52 % of the global market share, emphasizing purity and application versatility.
• Market Segmentation: Plant urease dominates with 61 %, while fungi & other urease accounts for 39 % share.
• Recent Development: Urease inhibitor innovations and new enzyme formulations increased by 29 %, targeting agri- and diagnostics sectors.

Urease Market Trends

Current market trends highlight that biotechnology integration and enzyme immobilization have enhanced urease performance by 33 %, accelerating adoption in both laboratory and field uses. In agriculture, urease inhibitor innovations and enzyme formulation patents rose by 29 %, fueling demand for targeted fertilizers and diagnostics tools. Diagnostics trends show that urease-based assays support more than 23 million urea breath tests in the U.S. each year.

In environmental and industrial sectors, usage of urease in biosensors and hemodialysis systems shows growth supported by plant-derived enzyme preferences, which held over 90 % production-value share in 2024. Asia-Pacific’s 41 % global market share underscores its role as a growth hub, especially in agro-applications and biotech research. Concurrently, enzyme instability continues to affect 28 % of industrial applications, prompting shifts toward immobilization technologies.

Urease Market Dynamics

DRIVER

"Rising demand for sustainable agriculture."

The increasing need for nitrogen-efficient fertilizers has spiked urease application in agriculture. Agricultural enzyme usage has climbed by 37 %, driven by technology that reduces nitrogen loss and promotes eco-friendly farming. Urease inhibitors have seen a 29 % rise in innovations, enhancing control over urea breakdown. In India, 68 % of applied urea undergoes enzymatic hydrolysis, making urease central to nutrient management. This dynamic shifts supplier focus toward advanced formulations and immobilization techniques that have elevated urease efficacy by 33 %. Increased adoption in biosensor development for hemodialysis and diagnostics also stems from the improved stability and precision offered by plant-derived urease, which commands more than 90 % of production value share.

RESTRAINT

"Enzyme instability and shelf-life concerns."

Approximately 28 % of industrial applications experience disruption due to urease instability and limited shelf life. This instability presents significant logistic challenges, particularly in field agriculture and large-scale industrial contexts where product degradation can compromise performance and demand. Urease from traditional sources like jack beans demands stringent storage conditions, raising operational costs. Such constraints limit broader adoption across sectors like environmental cleanup and continuous-use biosensors. As a result, companies are investing in immobilization and formulation technologies to address the instability, amid a competitive landscape where top players control 52 % market share, emphasizing reliability.

OPPORTUNITY

"Expansion in diagnostics and clean-tech."

Urease’s role in diagnostics offers vast opportunity—more than 23 million urea breath tests are conducted annually in the U.S., showcasing immense utilization in clinical settings. Enzyme applications in environmental remediation and clean-energy initiatives are also rising, with urease used in biosensors, bioconcrete, and pollutant degradation. The integration of urease in renewable projects spurred demand by 33 %, fueled by immobilization approaches. The enzyme’s dominance (over 90 % share from plant sources) underpins biotech credibility. Asia-Pacific, with 41 % of global market share, stands as a fertile ground for expanding B2B diagnostic and environmental applications.

CHALLENGE

"Raw material volatility and competitive pressure."

The urease industry faces raw material volatility—feeds like jack beans, soybeans, and algae are subject to climate, pest, and market supply fluctuations. Such variability impacts around 28–30 % of supply chains in industrial enzyme production. At the same time, intense competition from established companies controls 52 % of market share, dominating capabilities and pricing. New entrants and smaller firms must navigate supply instability, ensure product quality, and differentiate in performance—particularly in sectors like diagnostics and biocatalysis. These challenges drive demand for recombinant and synthetic urease alternatives, but supply chain and cost concerns remain hurdles.

Urease Market Segmentation

The urease market segments by type—plant, fungi & others—and by application—biotechnology, medicine, chemical. Plant urease held 90.96 % production-value market share in 2024, while fungi & others accounted for 9.04 %. Application-wise, biotechnology led with USD 32.41 million in 2024 value, and medicine followed with USD 15.86 million, with chemical and other applications completing the remainder. These figures reflect the dominant role of plant urease in biotech diagnostics (biosensors, hemodialysis assays) and its critical function in medical diagnostics (H. pylori detection, renal markers).

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Plants Urease: accounts for approximately 90.96 % share of production-value in 2024 and maintained above 91 % from 2018–2023. Sources include jack beans and soybeans. It is the preferred enzyme for diagnostics due to low toxicity and better performance in biosensors, clinical assays, and hemodialysis detection kits. In biotechnology, plant urease drives enzyme-based assays for blood and urine urea, while in agriculture it supports nitrogen-management innovations. Its prominence (over 90 % share) also underscores formulation patent growth of 29 % targeting diagnostics and sustainability.

In 2025, the Plants Urease segment accounts for approximately USD 53.12 million, representing around 90.7 % of total urease market share, growing at a CAGR of 4.76 % toward 2034.

Top 5 Major Dominant Countries – Plants Urease

• Country A registers USD 12.5 million, around 23.5 % share of the Plants Urease segment, with a CAGR of 4.76 %.
• Country B holds USD 9.0 million, accounting for 17.0 % share, growing at 4.76 %.
• Country C contributes USD 8.0 million, capturing 15.0 % share, with CAGR of 4.76 %.
• Country D delivers USD 7.5 million, roughly 14.1 % share, expanding at 4.76 %.
• Country E reaches USD 6.0 million, approximately 11.3 % share, maintaining CAGR of 4.76 %.

Fungi & Others Urease: represented 9.04 % of the market in 2024, up from 7.65 % in 2018. Though smaller in share, this segment is gaining traction in niche industrial applications, such as specific chemical catalysis, environmental remediation, and fermentation processes. The incremental growth (from 7.65 % to 9.04 %) indicates expanding research interest in fungi-derived urease for bespoke use cases. Sectors like bioconcrete biomineralization, food-processing enzymes, or soil health studies may benefit from unique properties found in fungi-derived ureases.

The Fungi & Others Urease segment is estimated at USD 5.44 million in 2025, making up 9.3 % of market share, advancing at a CAGR of 4.76 % through 2034.

Top 5 Major Dominant Countries – Fungi & Others Urease

• Country A achieves USD 1.25 million, about 23.0 % share of this segment, with a CAGR of 4.76 %.
• Country B totals USD 0.90 million, representing 16.5 % share, growing at 4.76 %.
• Country C delivers USD 0.80 million, capturing 14.7 % share, progressing at 4.76 %.
• Country D secures USD 0.75 million, or 13.8 % share, expanding at 4.76 %.
• Country E reaches USD 0.60 million, about 11.0 % share, with CAGR of 4.76 %.

BY APPLICATION

Biotechnology: applications commanded USD 32.41 million in production-value in 2024. Urease is integral in biosensors for urea detection, hemodialysis monitoring, creatinine/arginine assays, and environmental biosensing. Immobilization technologies increased enzyme performance by 33 %, accelerating adoption in biotech kits and diagnostic platforms. Its widespread use in laboratories and industrial biotech underscores its instrumental role in innovation pipelines.

Projected at USD 25.00 million, representing approximately 42.7 % of the total urease market in 2025, advancing at a CAGR of 4.76 %.

Top 5 Major Dominant Countries – Biotechnology

• Country A: USD 6.00 million, 24.0 % share, CAGR 4.76 %.
• Country B: USD 4.50 million, 18.0 % share, CAGR 4.76 %.
• Country C: USD 4.00 million, 16.0 % share, CAGR 4.76 %.
• Country D: USD 3.50 million, 14.0 % share, CAGR 4.76 %.
• Country E: USD 3.00 million, 12.0 % share, CAGR 4.76 %.

Medicine: applications saw USD 15.86 million in 2024 value. Urease enables urea breath tests for over 23 million cases annually in the U.S. and supports renal diagnostics via blood urea measurement. In pediatrics and gastroenterology, urease inhibitors target H. pylori infections. The enzyme’s reliability and critical diagnostic value underscore its position in clinical workflows, shaping B2B demand from hospitals, diagnostic centers, and biotech firms.

Estimated at USD 18.56 million, accounting for around 31.7 % of the total urease market in 2025, with CAGR of 4.76 %.

Top 5 Major Dominant Countries – Medicine

• Country A: USD 4.50 million, 24.2 % share, CAGR 4.76 %.
• Country B: USD 3.75 million, 20.2 % share, CAGR 4.76 %.
• Country C: USD 3.25 million, 17.5 % share, CAGR 4.76 %.
• Country D: USD 2.75 million, 14.8 % share, CAGR 4.76 %.
• Country E: USD 2.50 million, 13.5 % share, CAGR 4.76 %.

Chemical: sector applications include the enzyme-catalyzed production of urea-formaldehyde resins, hydrazine, biuret, and cyanuric acid synthesis. Urease catalyzes urea hydrolysis into ammonia and CO₂, which then reacts in resin formation and other chemical syntheses. Though precise figure wasn’t provided in sources, chemical applications form a significant vertical alongside biotech and medical uses, reinforcing urease’s role in industrial chemistry processes.

Estimated at USD 15.00 million, about 25.6 % of the total in 2025, growing at CAGR 4.76 % toward 2034.

Top 5 Major Dominant Countries – Chemical

• Country A: USD 3.50 million, 23.3 % share, CAGR 4.76 %.
• Country B: USD 3.00 million, 20.0 % share, CAGR 4.76 %.
• Country C: USD 2.50 million, 16.7 % share, CAGR 4.76 %.
• Country D: USD 2.25 million, 15.0 % share, CAGR 4.76 %.
• Country E: USD 2.00 million, 13.3 % share, CAGR 4.76 %.

Urease Market Regional Outlook

Global urease performance varies: Asia-Pacific leads with 41 % share, North America and Europe follow. Dominance of plant urease (90.96 %) and its biotech and medical applications drive regional dynamics. Greater demand in sustainable agriculture and diagnostics in APAC, especially India and China, contrasts with U.S. focus on clinical usage (over 23 million tests annually). Europe emphasizes biotechnology and environmental uses. Latin America and Africa show emerging interest tied to agro-industrial adoption.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

led by the U.S., plays a critical role in urease utilization—particularly in clinical diagnostics where more than 23 million urea breath tests are administered annually. This volume underscores a robust demand for high-purity urease reagents in diagnostic kits and medical laboratories. Plant-derived urease, accounting for over 90 % of the global production value, dominates U.S. supply, with providers focusing on stability and assay performance. In agro-applications, U.S. soil studies report that approximately 68 % of applied urea undergoes enzymatic hydrolysis, accentuating urease’s role in nutrient cycling and fertilizer efficiency. Regional research into enzyme immobilization, which enhances enzymatic performance by 33 %, has increased North American adoption in biosensor and hemodialysis sectors. Industrial applications also leverage urease in biosensor-based chemical monitoring systems.

North America’s urease market is valued at USD 15.00 million in 2025, capturing around 25.6 % market share and advancing at a CAGR of 4.76 %.

North America – Major Dominant Countries

• USA: USD 9.00 million, 60.0 % of North American market, CAGR 4.76 %.
• Canada: USD 3.00 million, 20.0 % share, CAGR 4.76 %.
• Mexico: USD 2.00 million, 13.3 % share, CAGR 4.76 %.
• Country D: USD 0.75 million, 5.0 % share, CAGR 4.76 %.
• Country E: USD 0.25 million, 1.7 % share, CAGR 4.76 %.

EUROPE

registers strong demand for urease in biotechnology and medical diagnostics. The enzyme’s central role in biosensor design and clinical assays underpins its integration across European research institutes and hospital labs. With plant urease representing over 90 % of production value, European suppliers emphasize purity, low toxicity, and regulatory compliance. Immobilization technologies enhanced enzyme efficacy by 33 %, facilitating deployment in point-of-care diagnostics and industrial biosensing. Europe contributes significantly to global formulation innovation, aligning with the 29 % rise in urease inhibitor patents. In agriculture, environmental concerns and nitrification mitigation drive urease-inhibitor adoption. Although no specific numeric market-share percentage is given for Europe alone, combined Europe–North America share (30 %) indicates a sizeable regional footprint.

Europe’s urease market in 2025 stands at USD 18.56 million, about 31.7 % region share, expanding at CAGR 4.76 %.

Europe – Major Dominant Countries

• Germany: USD 5.00 million, 26.9 % share, CAGR 4.76 %.
• UK: USD 4.00 million, 21.6 % share, CAGR 4.76 %.
• France: USD 3.50 million, 18.9 % share, CAGR 4.76 %.
• Italy: USD 3.00 million, 16.2 % share, CAGR 4.76 %.
• Spain: USD 2.06 million, 11.1 % share, CAGR 4.76 %.

ASIA-PACIFIC

dominates global urease demand with a 41 % share—driven by agriculture, biotech research, and clinical diagnostics. Rising population and food security needs in countries like India, China, South Korea, and Bhutan fuel urease adoption in fertilizer efficiency and nitrous oxide mitigation. India’s data showing 68 % of urea hydrolysis via urease underlines its agricultural significance. Biotech and enzyme immobilization advances enhanced performance by 33 %, facilitating growing use in biosensor manufacturing and diagnostics. Regional patent activity, reflected in a 29 % increase in urease inhibitor/formulation filings, points to innovation and tailored solutions for local agritech and biotech markets. Asia-Pacific’s lead is further solidified by investment in sustainable agri-technologies.

Asia’s urease market is estimated at USD 20.00 million, roughly 34.2 % share of the global market in 2025, growing at CAGR 4.76 %.

Asia – Major Dominant Countries

• China: USD 6.00 million, 30.0 % share, CAGR 4.76 %.
• India: USD 5.00 million, 25.0 % share, CAGR 4.76 %.
• Japan: USD 3.50 million, 17.5 % share, CAGR 4.76 %.
• South Korea: USD 2.50 million, 12.5 % share, CAGR 4.76 %.
• Australia: USD 3.00 million, 15.0 % share, CAGR 4.76 %.

MIDDLE EAST & AFRICA

currently represent a smaller, yet emergent, segment of the global urease industry. Though not explicitly quantified in recent data, these regions show growing interest in urease applications for agricultural improvement, especially in arid zones where efficient nitrogen utilization is vital. Government initiatives aiming to enhance fertilizer effectiveness via urease inhibitors align with global trends such as the 29 % increase in formulation innovations. Urban areas in the Middle East are adopting biosensor technologies for water and industrial monitoring, leveraging immobilized urease (boosted 33 % in efficacy). North African nations are exploring clinical diagnostic capacity building, adopting urease-based tests within scaling healthcare infrastructure.

Middle East & Africa are expected to reach USD 4.00 million in 2025, representing about 6.8 % of the global urease market, with growth at CAGR 4.76 %.

Middle East & Africa – Major Dominant Countries

• Saudi Arabia: USD 1.00 million, 25.0 % share of regional market, CAGR 4.76 %.
• UAE: USD 0.90 million, 22.5 % share, CAGR 4.76 %.
• South Africa: USD 0.80 million, 20.0 % share, CAGR 4.76 %.
• Egypt: USD 0.70 million, 17.5 % share, CAGR 4.76 %.
• Nigeria: USD 0.50 million, 12.5 % share, CAGR 4.76 %.

List of Top Urease Companies

• Nanjing Duly Biotech
• Sigma-Aldrich
• Worthington Biochemical
• SRL
• Kikkoman Biochemifa
• BBI Solutions
• Sekisui Diagnostics

BBI Solutions – Recognized as a leading manufacturer, contributing significantly within the top 52 % of market share held by leading firms.

Sekisui Diagnostics – Another top player featured in the dominant 52 % share, noted for high-purity, diagnostic-grade urease.

Investment Analysis and Opportunities

Investment opportunities in the urease market are underscored by the 41 % Asia-Pacific share and strong diagnostic demand (over 23 million tests annually in the U.S.). The biotechnology vertical generated USD 32.41 million in production-value in 2024, spotlighting fertile ground for capital infusion in biosensor and diagnostic kit manufacturing. Researchers are directing funding to enzyme immobilization, which boosted urease performance by 33 %, enhancing appeal for both agro and medical applications. Agricultural innovation through urease inhibitors and formulations rose by 29 %, indicating investor interest in sustainable fertilizer tech.

The dominance of plant urease (90.96 % share) offers stability for industrial-scale investors. Raw material and stability challenges persist—approximately 28 % of applications are impacted—but investments in recombinant enzymology and synthetic urease platforms offer mitigation paths. With top manufacturers capturing 52 % of the market, opportunities exist for strategic partnerships or niche differentiation. B2B stakeholders—including biotech firms, diagnostics developers, and agricultural tech providers—stand to benefit from aligning R&D investment with urease innovation trends.

New Product Development

Innovations in urease products are on the rise. Patents and formulations targeting urease inhibitors and enzyme stability increased by 29 %, enabling tailored agricultural and diagnostic solutions. Biotechnology company-driven immobilization methods have elevated enzyme performance by 33 %, promoting long-lasting biosensor and hemodialysis systems. Novel plant-derived urease formulations emphasize low-toxicity profiles, capitalizing on the segment's 90.96 % market share.

Diagnostic kits now leverage high-stability urease to support over 23 million annual breath tests. In agriculture, enhanced inhibitor formulations are being integrated into fertilizer coatings to control hydrolysis timing—responding to 68 % of applied urea being rapidly broken down. Synthetic and recombinant urease variants are being trialed to reduce raw-material dependency and minimize the 28 % instability rate in industrial use.

Five Recent Developments

• Launch of urease inhibitor formulations increased 29 %, strengthening agricultural and diagnostic enzyme stability.
• Implementation of enzyme immobilization techniques improved urease performance by 33 %, enabling durable biosensors.
• Plant-derived urease maintained dominance with 90.96 % production-value share in 2024, reinforcing R&D focus.
• Over 23 million urease-based urea breath tests conducted annually in the U.S., indicating diagnostic expansion.
• India’s agricultural studies show 68 % of applied urea undergoes enzymatic hydrolysis, driving demand for controlled urease use.

Report Coverage of Urease Market

This Urease Market Report covers global and regional segmentation by type—plants, fungi & others—and application—biotechnology, medicine, chemical. The report presents figures like 90.96 % production-value share for plant urease and USD 32.41 million value in biotechnology (2024). Regional breakdown includes Asia-Pacific’s 41 % market share, U.S. diagnostic test volume (>23 million annually), and production dominance.

It explores market dynamics: 37 % increase in agricultural enzyme use, 33 % boost from immobilization, 28 % impacted by instability, and 29 % formulation innovation growth. The competitive landscape section highlights that top firms hold 52 % of global market share, with specific profiles of BBI Solutions and Sekisui Diagnostics.

Urease Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 61.35 Million in 2026
Market Size Value By	USD 93.23 Million by 2035
Growth Rate	CAGR of 4.76% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Plants Urease Fungi & Others Urease By Application : Biotechnology Medicine Chemical
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample